Recent Updates
Recently added Catalysts
ACET Positive Sentiment

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Tuesday, July 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Adicet Bio, a clinical-stage biotechnology company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. CEO Chen Schor will engage in a fireside chat during the event scheduled for August 11-13, 2026, in Boston. This opportunity highlights the company's focus on developing allogeneic gamma delta T cell therapies.
Price reaction · baseline $8.12 (2026-07-21 close) · hit after-hours · clean, no other ACET news in the window
day 0 close · peak
+5.5%
day 1
+3.7%
day 3
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Adicet Bio is actively participating in a prominent industry conference.
  • The event provides a platform for CEO Chen Schor to share insights.
  • Focus on innovative therapies for autoimmune diseases and cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
1.9%
average across 4 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
ADI-212
Phase 1 · Prostate Cancer Metastatic

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30

Frequently Asked Questions

What is the date of the Canaccord Genuity Conference?

The conference will be held from August 11-13, 2026.

Who will represent Adicet Bio at the conference?

Chen Schor, the President and CEO, will participate.

What is the focus of Adicet Bio's therapies?

Adicet Bio focuses on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

ShareAdd on Google
Tags: ACET Adicet Bio Canaccord Genuity growth conference Chen Schor
Last updated: Jul 21, 2026

Biotech snapshot

Cash runway
$118M liquidity · $7M/mo burn
~16 mo
Low dilution risk
Lead asset
ADI-212Phase 1
Prostate Cancer Metastatic →

Catalyst track record

+12%
best trade around ACET's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACET.

See every catalyst's timing & PoA →